
|Videos|August 24, 2022
Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
Author(s)Sunandana Chandra, MD, MS
An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.
Advertisement
Episodes in this series

Advertisement
Related to this article

Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.

Given an 18-month prognosis for peritoneal mesothelioma in 2007, a mother shares the joy of tapping her son out at his Air Force basic training graduation.

A once-daily oral pill gives patients with symptomatic TGCT another option when surgery could cause more harm than good.

For World NET Cancer Day, CURE answers seven common questions about neuroendocrine tumors, from carcinoid syndrome and Ki-67 to dotatate PET scans and treatment options.

Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.

Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.

Most people with pancreatic cancer lose weight they didn't mean to. Here is how weight loss from poor digestion differs from cachexia, and what enzymes, eating strategies and appetite medicines can do.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
3
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
4
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
5

